Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Jeffrey J. Wallin, Johanna C. Bendell, Roel Funke, et al.
Nature Communications (2016) Vol. 7, Iss. 1
Open Access | Times Cited: 626

Showing 1-25 of 626 citing articles:

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn, Shukui Qin, Masafumi Ikeda, et al.
New England Journal of Medicine (2020) Vol. 382, Iss. 20, pp. 1894-1905
Open Access | Times Cited: 5282
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, et al.
New England Journal of Medicine (2018) Vol. 378, Iss. 24, pp. 2288-2301
Open Access | Times Cited: 3234
VEGF in Signaling and Disease: Beyond Discovery and Development
Rajendra S. Apte, Daniel S. Chen, Napoleone Ferrara
Cell (2019) Vol. 176, Iss. 6, pp. 1248-1264
Open Access | Times Cited: 2039
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Yosuke Togashi, Kohei Shitara, Hiroyoshi Nishikawa
Nature Reviews Clinical Oncology (2019) Vol. 16, Iss. 6, pp. 356-371
Closed Access | Times Cited: 1181
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott, Mahrukh Huseni, Michael B. Atkins, et al.
Nature Medicine (2018) Vol. 24, Iss. 6, pp. 749-757
Open Access | Times Cited: 1095
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 4, pp. 862-873
Open Access | Times Cited: 1000
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I. Rini, Thomas Powles, Michael B. Atkins, et al.
The Lancet (2019) Vol. 393, Iss. 10189, pp. 2404-2415
Closed Access | Times Cited: 876
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors
Shona Hendry, Roberto Salgado, Thomas Gevaert, et al.
Advances in Anatomic Pathology (2017) Vol. 24, Iss. 6, pp. 311-335
Open Access | Times Cited: 667
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Ming Yi, Dechao Jiao, Hanxiao Xu, et al.
Molecular Cancer (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 665
De-novo and acquired resistance to immune checkpoint targeting
Nicholas Syn, Michele W.L. Teng, Tony Mok, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 12, pp. e731-e741
Closed Access | Times Cited: 661
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Rakesh R. Ramjiawan, Arjan W. Griffioen, Dan G. Duda
Angiogenesis (2017) Vol. 20, Iss. 2, pp. 185-204
Open Access | Times Cited: 577
Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
Charlene M. Fares, Eliezer M. Van Allen, Charles G. Drake, et al.
American Society of Clinical Oncology Educational Book (2019), Iss. 39, pp. 147-164
Closed Access | Times Cited: 558
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
John D. Martin, Horacio Cabral, Triantafyllos Stylianopoulos, et al.
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 4, pp. 251-266
Open Access | Times Cited: 537
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Kabir A. Khan, Robert S. Kerbel
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 5, pp. 310-324
Closed Access | Times Cited: 527
Turning cold tumors into hot tumors by improving T-cell infiltration
Yuan‐Tong Liu, Zhi‐Jun Sun
Theranostics (2021) Vol. 11, Iss. 11, pp. 5365-5386
Open Access | Times Cited: 522
Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity
Mikhail Binnewies, Adriana M. Mujal, Joshua L. Pollack, et al.
Cell (2019) Vol. 177, Iss. 3, pp. 556-571.e16
Open Access | Times Cited: 516
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
Martina Schmittnaegel, Nicolò Rigamonti, Ece Kadioglu, et al.
Science Translational Medicine (2017) Vol. 9, Iss. 385
Closed Access | Times Cited: 509
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Ming Yi, Dechao Jiao, Shuang Qin, et al.
Molecular Cancer (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 500
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
Michael S. Lee, Baek‐Yeol Ryoo, Chih‐Hung Hsu, et al.
The Lancet Oncology (2020) Vol. 21, Iss. 6, pp. 808-820
Closed Access | Times Cited: 473
Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
John D. Martin, Giorgio Seano, Rakesh K. Jain
Annual Review of Physiology (2019) Vol. 81, Iss. 1, pp. 505-534
Open Access | Times Cited: 406
Immunotherapy and targeted therapy combinations in metastatic breast cancer
Francisco J. Esteva, Vanessa M. Hubbard-Lucey, Jun Tang, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 3, pp. e175-e186
Closed Access | Times Cited: 405
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
János L. Tanyi, Sara Bobisse, Eran Ophir, et al.
Science Translational Medicine (2018) Vol. 10, Iss. 436
Closed Access | Times Cited: 382
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
Priti S. Hegde, Jeffrey J. Wallin, Christoph Mancao
Seminars in Cancer Biology (2017) Vol. 52, pp. 117-124
Closed Access | Times Cited: 375
The cancer-immunity cycle: Indication, genotype, and immunotype
Ira Mellman, Daniel S. Chen, Thomas Powles, et al.
Immunity (2023) Vol. 56, Iss. 10, pp. 2188-2205
Open Access | Times Cited: 345
Beyond immune checkpoint blockade: emerging immunological strategies
Shawn P. Kubli, Thorsten Berger, Daniel Vilarim Araújo, et al.
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 12, pp. 899-919
Closed Access | Times Cited: 339
Page 1 - Next Page

Scroll to top